Teva releases late-stage trial results for Qnaze HFA

JERUSALEM — An investigative treatment for allergies made by Teva Pharmaceutical Industries appears to work, according to results of a late-stage clinical trial released Monday.

Teva said phase-3 data from a study of Qnaze HFA (beclomethasone dipropionate), designed to be inhaled through the nose, was effective in treating patients with seasonal allergic rhinitis, while safety results were similar to those for placebo. Data from the study were presented at the annual meeting of the American College of Allergy, Asthma & Immunology in Phoenix.

“The results of this pivotal clinical trial suggest that Qnaze HFA may be efficacious and safe for individuals seeking relief from the nasal symptoms associated with their seasonal allergies,” study lead investigator Jay van Bavel said.